Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Double Blind Study of Vigabatrin for the Treatment of Cocaine Dependence

This study has been completed.
Sponsor:
Collaborator:
Catalyst Pharmaceutical Partners, Inc
Information provided by:
New York University School of Medicine
ClinicalTrials.gov Identifier:
NCT00527683
First received: September 10, 2007
Last updated: April 7, 2008
Last verified: April 2008

September 10, 2007
April 7, 2008
April 2007
November 2007   (final data collection date for primary outcome measure)
Three consecutive weeks of negative urine tests (benzoyl ecgonine) for cocaine use (no slips allowed). [ Time Frame: These must be the last three weeks (7,8,9) of the trial. ] [ Designated as safety issue: No ]
Three consecutive weeks of negative urine tests (benzoyl ecgonine) for cocaine use (no slips allowed). [ Time Frame: These must be the last three weeks (7,8,9) of the trial. ]
Complete list of historical versions of study NCT00527683 on ClinicalTrials.gov Archive Site
  • 3 consecutive weeks of negative urines (one slip allowed) [ Time Frame: Last 3 weeks (7,8,9) of the trial ] [ Designated as safety issue: No ]
  • cocaine craving [ Time Frame: Weeks 1, 5,9 ] [ Designated as safety issue: No ]
  • 3 consecutive weeks of negative urines (one slip allowed) [ Time Frame: Last 3 weeks (7,8,9) of the trial ]
  • Longest number of consecutive days abstinent, the number of days until onset of 21 consecutive days abstinent, the number of days to relapse after 3 days of abstinence [ Time Frame: Duration of the 9 week trial ]
Not Provided
Not Provided
 
Double Blind Study of Vigabatrin for the Treatment of Cocaine Dependence
Double-Blind, Randomized, Placebo- Controlled Trial of Vigabatrin for Short Term Abstinence From Cocaine in Cocaine Dependent Parolees

The primary objective of this study is to assess the efficacy of vigabatrin for the treatment of cocaine dependence, based on the twice-weekly qualitative urine toxicologies for cocaine. Based on two prior unblinded human studies and 15 years of animal studies, this 100 subject double- blind, randomized study is designed to show if with vigabatrin treatment but not placebo, even non-hospitalized cocaine dependent individuals with ready access to cocaine will become cocaine abstinent if they are self motivated to stop their cocaine habit. To accomplish this, cocaine dependent subjects will be randomly assigned to either a placebo or vigabatrin treatment group and treated for a nine week period. The primary hypothesis is that as compared to the placebo arm, the vigabatrin treatment arm will show a significant increase in the number of subjects who are abstinent for the final 3 weeks of the study.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Cocaine Dependence
  • Drug: Vigabatrin
    crystalline drug dissolved in orange juice, dosage escalates from 500 mg twice daily to 1.5 g twice daily over a 3 week period. This dose is maintained for 4 weeks and then tapered to zero over the next two weeks
    Other Names:
    • Sabril
    • CPP 109
    • gamma vinyl GABA
    • GVG
  • Drug: Placebo
    orange juice is administered twice daily in containers indistinguishable from the treatment arm.
  • Behavioral: Group therapy
    Participants attend group sessions once a week
  • Active Comparator: A
    Subjects will receive vigabatrin in escalating doses to 3 grams per day over three weeks, continued for 4 weeks and then tapered to zero over the next 2 weeks.
    Interventions:
    • Drug: Vigabatrin
    • Behavioral: Group therapy
  • Placebo Comparator: B
    Orange juice and administration identical to Arm A.
    Interventions:
    • Drug: Placebo
    • Behavioral: Group therapy

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
100
November 2007
November 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

In order to participate in the study, subjects must

  • Be at least 18 years of age and no older than 55 years of age.
  • Weigh more than 100 pounds.
  • Have a DSM-IV diagnosis of cocaine dependence.
  • Be seeking treatment for cocaine dependence.
  • Have a urine sample positive for qualitative cocaine toxicology at initial screening.
  • Have the ability to understand, and having understood, provide written informed consent to comply with the treatment protocol.
  • Have a history and brief physical examination that demonstrate no clinically significant contraindication for participating in the study, in the judgment of the admitting physician and the Principal Investigator.
  • Have normal, or, if necessary, corrected visual acuity, visual fields, and normal fundoscopy findings

Exclusion Criteria:

  • In order to participate in the study, subjects must not:

    • Meet DSM-IV criteria for current dependence on any psychoactive substance other than cocaine, alcohol, nicotine, or marijuana or physiological dependence on alcohol requiring medical detoxification.
    • Have neurological or psychiatric disorders such as: psychosis, bipolar illness, major depression, organic brain disease, dementia, any disorder which would require ongoing treatment or which would make study agent compliance difficult, history of suicide attempts assessed and/or current suicidal ideation/plan.
    • Have serious medical illnesses or other potentially life threatening or progressive medical illness other than addiction that may compromise subject safety or study conduct.
    • Have a history of traumatic head injury.
    • Be mandated by a court to obtain treatment for cocaine dependence.
    • Have been treated for cocaine addiction, or abstained from cocaine use for a significant period, within the 6 months preceding screening.
    • Be unable to complete the study protocol because of probable incarceration or relocation from the clinical area.
    • Have AIDS (although AIDS is an exclusion criterion, a positive antibody titer to HIV is not).
    • Have active syphilis that has not been treated or refuse treatment for syphilis
    • Have a history of neuroleptic malignant syndrome.
    • Have known or suspected hypersensitivity to vigabatrin or any other GABAergic drug.
    • Have received a drug with known potential for toxicity to a major organ system within 30 days prior to study entry (e.g., isoniazid, methotrexate).
    • Have participated in any experimental study within 4 weeks, or participated in any clinical trial utilizing vigabatrin.
    • Be pregnant or lactating.
    • Have any clinically significant abnormal laboratory value.
    • Have had electroconvulsive therapy with the 3 months preceding screening.
    • Have had any opiate-substitutes (methadone, LAAM, buprenorphine) within 2 months preceding screening.
    • Have a history of i.v. cocaine (or other psychoactive drug) use within 2 months preceding screening.
    • Have a current or past history of seizure disorder, including alcohol- or stimulant related seizure, febrile seizure, or significant family history of idiopathic seizure disorder.
    • Have a visual field defect, or factor predisposing to visual field defects, including glaucoma, severe myopia, retinal disorder, cataracts, diabetes or uncontrolled hypertension.
    • Have my illness, condition, and use of medications, in the opinion of the Principal Investigator and the admitting physician, which would preclude safe or successful completion of the study.
    • Be using vigabatrin or any medication that could interact adversely with vigabatrin administration, based on the longest time interval of A or B below:

      • A) Five half-lives of other medication or active metabolite(s), whichever is longer;
      • B) Two weeks.
    • Be lactose intolerant.
Both
18 Years to 55 Years
No
Contact information is only displayed when the study is recruiting subjects
Mexico
 
NCT00527683
H06-152
Yes
Jonathan D. Brodie, PhD, MD, Professor, Dept. of Psychiatry, New York University School of Medicine
New York University School of Medicine
Catalyst Pharmaceutical Partners, Inc
Principal Investigator: Jonathan D Brodie, Ph.D., M.D. New York University School of Medicine
Study Director: Emilia Figueroa, M.D. Clinica Integral de Tratamiento Contra las Adicciones, S.A de C.V.
New York University School of Medicine
April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP